Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...

Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to cquire InflammX Therapeutics during an agreed-upon option period based on ...

Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...

Heart disease is often associated with the heart and arteries, but its effects extend far beyond the cardiovascular system.

City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based ...

The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

Over 537 million people globally suffer from diabetes, with 227 million in Asia Pacific. More than half may develop diabetic ...

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study, pu ...

"Our approach achieved remarkably high levels of gene correction," said Dr. György. "We observed average editing rates of 75% ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Pravin U. Dugel, MD, Ocular’s Executive Chairman, President and CEO, will provide an update regarding the enrollment status of SOL-R, the Company’s second registrational trial of AXPAXLI™ for the ...